Back in March, at the first hearing in consolidated litigation over allegedly undisclosed side effects from Ozempic and other diet drugs, plaintiffs lawyers told Philadelphia federal judge Gene Pratter that they’d already agreed on a slate of four lawyers to lead the mass tort case. On Wednesday, Pratter appointed those same four lawyers as lead counsel in the multidistrict litigation against diet drugmakers Novo Nordisk and Eli Lilly. But Pratter was no rubber stamp, writes Alison Frankel. In fact, Frankel says, the judge devised a leadership selection process that other MDL judges should consider adopting.
Check out other recent pieces from our columnists: Alison Frankel and Jenna Greene
|
Additional writing by Sahal Muhammed.
|
